The present invention relates to 6-(1-methyl-1 H-pyrazol-4-yl)-2-3-[5-(2-morpholin- 4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate, its solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
本发明涉及6-(
1-甲基-1H-
吡唑-4-基)-2-3-[5-(2-
吗啉基-4-基-乙
氧基)
嘧啶-2-基]-
苄基}-2H-
吡啶并嗪-3-
酮二
氢磷酸盐、其溶剂结晶体形态的制造方法以及它们在治疗和/或预防由激酶信号传导的抑制、调节和/或调节引起、介导和/或传播的生理和/或病理状况中的使用,特别是通过抑制
酪氨酸激酶的抑制,例如癌症等病理状况。